The Clinical Research Of Temozolomide Standard Treatment Of Early Postoperative Contrast To The Standard Program Plus Temozolomide Chemotherapy For Glioblastoma Multiforme Cell Tumor

Object:Evaluation efficacy and safety of temozolomide in contrast to the standard program of standard treatment plus early postoperative temozolomide chemotherapy for newly diagnosed glioblastoma multiforme tumorMethods:The 30 newly diagnosed glioblastoma pationts were divided into group A and B. A group of patients were assigned standard chemotherapy, B group were treated with both early chemotherapy and standard chemotherapy for 2 years, and observe the effect.Results:The total number of patients is 30, with A group of 15 persons and B group of 15 persons. The overall survival rate of A group was 73.33%, and the overall survival rate of B group was 80.00%; The progression-free survival rate of A group was 20.00%, and the progression-free survival rate of B group was 30.33%.Conclusion:The temozolomide standard treatment of early postoperative can not be significantly increased survival rate and Progression-free survival of the patients.